VRDN Q3 2022 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+474.5% YoY

Gross Profit

-$21M-1751.0% margin

Operating Income

-$30M-2492.5% margin

Net Income

-$29M-2418.8% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

+366.8%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$441M

Total Liabilities

$32M

Stockholders' Equity

$409M

Cash & Equivalents

$344M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$208,000	+474.5%
Gross Profit	-$21M	-$8M	-164.4%
Operating Income	-$30M	-$14M	-110.7%
Net Income	-$29M	-$14M	-105.8%

Revenue Segments

Collaboration Revenue

$1M100%